02 August, 2017
Renaissance Technologies LLC owned about 0.34% of Clovis Oncology worth $9,767,000 as of its most recent SEC filing. The hedge fund run by Mitchell Blutt held 2.73M shares of the health care company at the end of 2016Q4, valued at $121.31 million, down from 3.53M at the end of the previous reported quarter. The Coca-Cola Company has 4 buy ratings, 16 holds and 0 sells even after the stock tumbled -1.26% from its high of $46.42 to a $196.32 billion market value through last close. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Clovis Oncology by 71.4% in the first quarter.
Mitchell Blutt decreased its stake in Clovis Oncology Inc (CLVS) by 22.67% based on its latest 2016Q4 regulatory filing with the SEC. Current trade price levels places CLVS's stock about -14.72% away from the 52-week high and closed 518.60% away from the 52-week low. LLC bought a new position in shares of Clovis Oncology during the first quarter worth about $4,617,000. (NASDAQ:CLVS)'s ATR is 4.97. Why are the underperforming company shares going higher? On a similar note, the stock is 10.28% above its 50-day moving average, providing a measure of support for short positions.
Clovis Oncology (NASDAQ:CLVS) has insider ownership of 17.40% and institutional ownership of 90.01%. The biopharmaceutical company reported ($1.33) EPS for the quarter, topping the Zacks' consensus estimate of ($1.43) by $0.10. Highbridge Cap Limited Com has 0.01% invested in Clovis Oncology Inc (NASDAQ:CLVS).
TRADEMARK VIOLATION WARNING: This news story was originally posted by Stock Observer and is the property of of Stock Observer. This volatility measure use for multipurpose in judging the underlying price momentum as well as the rate of change in CLVS's price. Cann initiated coverage on shares of Clovis Oncology in a research note on Thursday, June 22nd. Oppenheimer began coverage of CLVS with an initial rating of "Market Perform". Their price objective ranges between $50.00 and $125.00. The consensus target price is $17.50 with 2 firms rating the stock a strong buy, 0 firms rating the stock a buy, 6 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell. ValuEngine downgraded Clovis Oncology from a "hold" rating to a "sell" rating in a research report on Friday, May 19th. The stock has "Buy" rating by Credit Suisse on Tuesday, July 18. Roth Capital maintained it with "Buy" rating and $35 target in Monday, November 2 report. The stock was sold at an average price of $61.82, for a total transaction of $185,460.00. Following the sale, the insider now owns 200,583 shares of the company's stock, valued at approximately $12,400,041.06. Opdivo, for instance, fetched Bristol-Myers Squibb almost $1.2 billion during the second quarter, according to the company's latest 10-Q filing with the Securities and Exchange Commission. Zooming in closer, company stock has been 2.78% for the quarter, -0.68% over the past month, and 0.18% over the past week.
Clovis Oncology, Inc.is a biopharmaceutical company which focuses on acquiring, developing and commercializing cancer treatments in the United States, Europe and other worldwide markets. The Company's product candidates include Rociletinib, Rubraca and Lucitanib. Its commercial product Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP), inhibitor of PARP1, PARP2 and PARP3 approved in the United States by the Food and Drug Administration (FDA), as monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the fix of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy based on an FDA-approved companion diagnostic for Rubraca.
